^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Rectal cancer: CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE...Patient appropriate for intensive therapy…Initial therapy...FOLFOXIRI ± bevacizumab...FOLFOX ± bevacizumab...CAPEOX + bevacizumab...Patient not appropriate for intensive therapy...Capecitabine ± bevacizumab...5-FU ± leucovorin ± bevacizumab...UNRESECTABLE METACHRONOUS METASTASES...Previous adjuvant FOLFOX/CAPEOX within past 12 months...(FOLFIRI or irinotecan) ± (bevacizumab...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...Trifluridine + tipiracil ± bevacizumab...Systemic therapy for advanced or metastatic disease…IROX + bevacizumab
Secondary therapy:
FOLFOX; FOLFOXIRI; IROX; 5-fluorouracil + leucovorin calcium; FOLFIRI; 5-fluorouracil; trifluridine/tipiracil; irinotecan; CAPOX; capecitabine
